AstraZeneca (LON: AZN)‘s stock had its “underweight” rating restated by analysts at JP Morgan Cazenove in a research report issued to clients and investors on Friday. They currently have a $41.54 (2750 GBX) price target on the stock.

A number of other firms have also recently commented on AZN. Analysts at Societe Generale reiterated a “sell” rating on shares of AstraZeneca in a research note to investors on Wednesday. They now have a $40.03 price target on the stock. Separately, analysts at Morgan Stanley raised their price target on shares of AstraZeneca from $45.62 to $50.00 in a research note to investors on Wednesday. They now have an “equal-weight” rating on the stock. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca in a research note to investors on Tuesday. They now have a $42.30 price target on the stock.

Ten investment analysts have rated the stock with a sell rating and eleven have given a hold rating to the company. AstraZeneca has an average rating of “Hold” and an average target price of $45.21 (2993 GBX).

Shares of AstraZeneca (LON: AZN) opened at 3133.00 on Friday. AstraZeneca has a 52 week low of GBX 2578.50 and a 52 week high of GBX 3171.50. The stock’s 50-day moving average is currently GBX 2919.40. The company’s market cap is £39.069 billion.

AstraZeneca PLC (LON: AZN) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.